ScripsAmerica's Specialty Pharmacy Announces $3.75
Post# of 7769
Posted On: 03/03/2015 8:01:37 AM
ScripsAmerica's Specialty Pharmacy Announces $3.75 Million in Approved Orders During February
ScripsAmerica's Specialty Pharmacy Announces $3.75 Million in Approved Orders During February
TYSONS CORNER, Va., March 3, 2015 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (OTCBB:SCRC) today announced that its wholly owned subsidiary, Main Avenue Pharmacy, reported $3,755,214 in approved orders during February of 2015.
"$3.75 million in approved orders for the month of February is on pace with our projections for Main Avenue Pharmacy. As we had announced last month, the first two months of each calendar year typically bring a decrease in prescription reimbursements due to renewing deductibles, which affects Main Avenue's revenues. Also affecting revenues are the fact that February is a short month and this year, we also experienced some closures due to bad weather," commented ScripsAmerica's CEO, Bob Schneiderman.
"That being the case, Scrips expects Main Avenue's March sales to increase and reach a level closer to those the Company recorded at the end of 2014. Additionally, we are excited to add our diabetic supply program which has been performing well to begin 2015," Schneiderman added.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: Seal Point Consulting, LLC
888-959-7095
ir@sealpointconsulting.com
(MORE TO FOLLOW) Dow Jones Newswires
March 03, 2015 08:00 ET (13:00 GMT)
ScripsAmerica's Specialty Pharmacy Announces $3.75 Million in Approved Orders During February
TYSONS CORNER, Va., March 3, 2015 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (OTCBB:SCRC) today announced that its wholly owned subsidiary, Main Avenue Pharmacy, reported $3,755,214 in approved orders during February of 2015.
"$3.75 million in approved orders for the month of February is on pace with our projections for Main Avenue Pharmacy. As we had announced last month, the first two months of each calendar year typically bring a decrease in prescription reimbursements due to renewing deductibles, which affects Main Avenue's revenues. Also affecting revenues are the fact that February is a short month and this year, we also experienced some closures due to bad weather," commented ScripsAmerica's CEO, Bob Schneiderman.
"That being the case, Scrips expects Main Avenue's March sales to increase and reach a level closer to those the Company recorded at the end of 2014. Additionally, we are excited to add our diabetic supply program which has been performing well to begin 2015," Schneiderman added.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: Seal Point Consulting, LLC
888-959-7095
ir@sealpointconsulting.com
(MORE TO FOLLOW) Dow Jones Newswires
March 03, 2015 08:00 ET (13:00 GMT)
(0)
(0)ScripsAmerica Inc (SCRC) Stock Research Links
Scroll down for more posts ▼